Pliant Therapeutics, Inc. (PLRX) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital
May 7, 2024 6:19 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "PLRX's IPF program remains on track with the ph.IIb expected to complete enrollment 1Q25. While this likely... More
Pliant Therapeutics (PLRX) PT Lowered to $44 at Citi
May 7, 2024 5:46 AM EDTCiti analyst David Lebowitz lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $44.00 (from $45.00) while maintaining a Buy rating.
The analyst comments "Pliant reported 1Q24 financial results and provided an update on the status of its pipeline programs. Over the... More



